2020
KING SKYFRONTCom panies and O rganizat ions l i s t

Kawasaki INnovation Gateway at SKYFRONTK a w asak i INnovati on Ga te wa y a t S KYF RON T

69

companies
and organizations

E m ployment

1,500

staﬀ

500

Researchers

300

Ph.D.
As of March 31, 2020

C o n te n ts
1 AccuRna, Inc.
●
2 ALBA Corporation ANY laboratory · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · 4●
3 AS ONE Corporation, Solution Research Laboratory●
4 BIOTECH LAB INC. · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · 5●
5 Braizon Therapeutics, Inc.
●
6 BrightPath Biotherapeutics Co., Ltd. · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · 6●
7 Central Institute for Experimental Animals (CIEA)●
8 Create Medic Co., Ltd. R&D Center · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · 7●
9 DOJINDO Laboratories●
10 FUJIFILM Toyama Chemical Co.,Ltd. Kawasaki Lab. · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · 8●
11 Gene Therapy Research Institution Co., Ltd●
12 Japan Radioisotope Association Kawasaki Technical Development Center · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · 9●
13 Johnson & Johnson Institute, Tokyo Science Center●
14 JSR Corporation●
15 Kanagawa Institute of industrial Science and Technology (KISTEC) Tonomachi Branch · · · · · · · · · · · · · · · · · · 10●
16 Kawasaki City Institute for Public Health●
17 Kawasaki Environment Research Institute (KERI)●
18 KAWASAKI INSTITUTE OF INDUSTRIAL PROMOTION Innovation Center of NanoMedicine(iCONM) · · · · · 11●
19 keio University Frontier Research＆Education Collaboration Square at Tonomachi（Tonomachi Town-Campus）●
20 Life Science Institute, Inc. Production Division, Tonomachi CPC · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · 12●
21 Material Research Center Co., Ltd●
22 Medtronic Japan Co.,Ltd. Medtronic Innovation Center●
23 Metcela Inc. · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · 13●
24 Middle Molecule IT-based Drug Discovery Laboratory, Tokyo Institute of Technology●
25 MITSUBISHI LOGISTICS CROPORATION●
26 NanoCarrier Co., Ltd.
●· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · 14

27 NANOEGG® Research Laboratories, Inc.
●
28 National Insutitute of Health Sciences●
29 PeptiDream Inc. · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · 15●30 PharmaBio Corporation●
31 Pharmacological Evaluation Institute of Japan (PEIJ), General Incorporated Association · · · · · · · · · · · · · · · · 16●
32 Riken Genesis Co.,Ltd.
●33 SBI Pharma Co., Ltd.
●34 Sumitomo Dainippon Pharma Co., Ltd· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · 17●
35 Sysmex Corporation●
36 Takara Bio Inc. · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · 18●

COMPANY PROFILES

AccuRna, Inc.

O l i g o n u c l e ti d e stherapeutics

RNAD r u g D e l i v e r y S y s te m

R&D of oligonucleotides therapeutics especially forcusing on DDS
AccuRna, a pre-clinical stage biotechnology company founded in late 2015, has proprietary polymer-based
delivery platforms designed for short chain RNA/DNA and mRNA which have been investigated and invented
by Prof. Kataoka and his colleagues. With its delivery platform, AccuRna is creating RNA therapeutics by using
a combination of “platform business” and “pipeline business” as a pharmaceutical company.

Innovation Center of NanoMedicine, 3-25-14, Tonomachi, Kawasaki-ku,

1

Kawasaki City, Kanagawa Prefecture, 210-0821+81-44-400-1045
tyoshida@accurna.com（Testuo Yoshida, Ph.D.）https://accurna.com/

ALBA Corporation
ANY laboratory

p o s ta l te s t i n g s e r v i c e s

Providing medical services, mainly postal testing services.

Conducting R&D for testing methods for early detection of sexually transmitted infections.
Alba Corporation provides medical services, mainly postal testing services (especially in STD ﬁeld), based on
the corporate philosophy of “making your health management more close” .
We have created a follow-up system with expert consultations and coordination with medical professionals.
We provide not only testing opportunities but information of prevention as well to increase prevention
awareness.
At our laboratory, we aim to contribute to society through collaborating with various research institutions,conducting R&D for testing methods which contribute to early detection, creating new medical services for
consumers.

+81-44-277-2225
lise-kanri@albacorp.co.jp04ServiceproviderAS ONE Corporation,
Solution Research Laboratory

Singlecell picking

Whole genome
imaging

G e nee x p r e s s ion

C e l l c u l t u retr a i n i n g c o u rs e

Service provider for cell cultures, gene expression
and whole genome imaging analyses

AS ONE has been providing a comprehensive supply of research instruments and consumables for use inlaboratories. AS ONE Solution Research Laboratory in KING SKYFRONT is a service provider to oﬀer single cell
picking, gene expression proﬁling, and whole genome imaging by using cutting-edge instruments andtechnologies in the ﬁeld in order to support basic and translational research. We are not only bringing an
opportunity to obtain high quality results from those instruments for researchers, but we are also creating
new applications to support customers who already installed those instruments.
Apart from being a service provider, we provide cell culture facilities in our laboratory to hold a training
course for qualifying cell culture specialists under the mentorship of trainers from The Japanese Tissue
Culture Association. Hence, we would like to become a hub for connecting technologies, human resources,
and ideas in order to provide a comprehensive solution to your research.
LIC-R219, 3-25-22, Tonomachi, Kawasaki-ku, Kawasaki, Kanagawa 210-0821 Japan+81-(0)44-577-7210
tonomachi-lab@so.as-1.co.jp（Sumiyo Mimura）
https://www.as-1.co.jp/en/

3

S e l l i n g l a b p r o d u c ts , e q u i p m e n t s a n d r e a g e n t s

BIOTECH LAB INC.

M a n a g i n g r e n t a l l a b o r a to r y a n d L I C O p e n L a b o r a t o ry
Moving and building new laboratory

A whole seller of lab products in life science market
BIOTECH LAB INC. is a whole seller of lab products in the KINGSKYFRONT. We have been handling lab
products like chips, equipments and reagents, and introducing outsourcing service of life sciences forcustomers.
Additionally, we have been managing rent laboratory space where basic lab equipments were installed.
Researchers can conduct experiment of molecular biology and cell culture in our rental laboratory understandard bio-safety level P2 and BSL2 condition. We have been receiving lots of inquiries on rental laboratory
service than we expected. And we have started on the management LIC Open Laboratory since April 2020 .
This lab is equipped with high-performance research instruments and devices like FCM.
We have many experiences to move and build new laboratory and can perform appropriate consultation forresearchers.
Do not hesitate to contact us if you need our assistance.

Life Innovation Center. 202, 3-25-22 Tonomachi, Kawasaki Kawasakiku, Kanagawa,210-0821+81-90-6296-3135
h-kakuta@bioteclab.co.jp（Hiromi Kakuta）
05

About BIOTECH LAB INC.

https://www.bioteclab.co.jp/

About LIC Open Laboratory

http://lic-openlab.com/

Braizon Therapeutics, Inc.

Drug Delivery
S y s te m

B l o o d - B r a i n B arrier

Drug Discovery and Development

Applying and implementing, within the ﬁelds of medicine and life science,
innovative technology for the delivery of drugs to the brain

Braizon Therapeutics, Inc. was established with the aim of applying and implementing, within the ﬁelds of
medicine and life science, innovative technology for the delivery of drugs to the brain as the outcome ofcollaborative research by Professor Kazunori Kataoka from the Graduate School of Engineering/Medicine, theUniversity of Tokyo and Professor Takanori Yokota from the Graduate School of Medical and Dental Sciences,
Tokyo Medical and Dental University.

254,Entrepreneur Lab.,Southern Research Building., The University of Tokyo 7-3-1,
Hongo, Bunkyo-ku, Tokyo 113-8485+81-3-5805-3417
info@braizon.com
http://www.braizon.com/

BrightPath Biotherapeutics Co., Ltd.

5

Cancer Immunotherapy

Cancer Immunotherapy
BrightPath is a clinical stage biopharmaceutical company focused on the development of novel cancer
immunotherapies to transform cancer treatment for refractory or progressive cancers that cannot be treatedwith conventional standard therapies. In addition to cancer peptide vaccines currently in clinical trials in the
United States(combination with an immune checkpoint inhibitor), BrightPath is actively involved in developing
cell therapies, immunomodulatory antibodies and new drugs targeted at cancer speciﬁc neoantigens.

Kojimachi Central Building 7F, 2-2-4 Kojimachi, Chiyoda-ku, Tokyo
+81-3-5840-7697
sugawara̲t@brightpathbio.com（Takaaki Sugawara）
https://www.brightpathbio.com/english/index.html
06Central Institutefor Experimental Animals (CIEA)

experimental animal
humanized
animala n i m a l e x p e r i m entaionmouse

m a r m os etresearch investigation concerning experimental animals
and dissemination of research results

the CIEA seeks to contribute to the health and welfare of humankind through development of quality
humanized animals with a stable reproduction level, and the research of human diseases and clariﬁcation of
their causes.

73-25-12 Tonomachi, Kawasaki-ku, Kawasaki, 210-0821+81-44-201-8510
ciea-info@ciea.or.jp（Mr. Hidenori Yokoyama, General Aﬀairs Department ）https://www.ciea.or.jp/en/index.html

Create Medic Co., Ltd. R&D Center

DisposableC a th e te r

S i l ic on

Research, manufacture and sale of medical appliances
Since the establishment of Create Medic Group, we have been devoting ourselves under our management
philosophy of “quality of life,” dedicating our lives to the research, development and manufacture of more
eﬀective disposable medical devices made of silicone resin. This material has remarkable properties
concerning safety and other beneﬁts. In this way, we hope to support medical practices in the lofty purposeof maintaining and preserving life and to respond to more complex needs in the medical workplace. Oureﬀorts have yielded Japan's ﬁrst manufactured silicone catheter, earning us a high level of recognition both
inside and outside Japan.

3-25-6 Tonomachi, Kawasaki-ku, Kawasaki, Kanagawa 210-0821+81-44-577-7790
k-kadoya@createmedic.co.jp（Kadoya Kiyoshi）

http://www.createmedic.co.jp/english/
07

DOJINDO Laboratories

cancerimmunitym e t a bol is m

Development of chemical reagents for cellular functional analysis
Since the latter half of the 1970's, DOJINDO Laboratories has been at the forefront of technologicalinnovations and developed a number of analytical reagents to help in the progress of scientiﬁc andtechnological research. Today, these products are widely used by many state-of-the-art researchorganizations, such as universities, medical institutions, research institutes, factories and so forth. Due to thedramatic progress in the ﬁeld of genetic research, recent expectations have been that reagents will play amore important role in this research ﬁeld. For the purpose of understanding these scientiﬁc and technologicalchanges without delay, we established an Innovative Research Center in Kawasaki.

LIC218, 3-25-22, Tonomachi, Kawasaki-ku, Kawasaki, Kanagawa 210-0821 Japan+81-44-201-7590
info@dojindo.co.jp（Yuya Ouchi）

https://www.dojindo.com/

FUJIFILM
Toyama Chemical Co.,Ltd.
Kawasaki Lab.

PET

Tumor

Individual9
A l z h e i mer
Diagnosis

Supply of radiopharmaceuticals for PET

and R&D of the formulation for individualized medicine
In collaboration with FUJIFILM, which conducts research on new drugs, we will develop novel radiologicaldiagnostic and therapeutic drugs in the ﬁelds of "cancer", "central nervous system disease" and "infectious
disease" with unmet medical needs.

3-25-15, Tonomachi, Kawasaki-ku, Kawasaki, Kanagawa 210-0821 Japan+81-44-277-8281
hiroki.ashino@fujiﬁlm.com（Hiroki Ashino）

http://ﬀtc.fujiﬁlm.co.jp/en/index.html
08

Gene Therapy
Research Institution Co., Ltd

G e n e th e r a p y

A A V v e c t orDevelopment of gene therapy
Gene therapy is deﬁned as “the administration of a gene or cells with introduced genes into the human bodyto treat diseases” , according to the MEXT and MHLW in Japan. Gene therapy research is progressing
globally. In Japan, clinical studies have already been conducted for some diseases. The age of gene therapy isabout to begin. In our research, we have found a unique gene therapy technique that is expected to havegreat therapeutic eﬀects: an innovative approach using the highly safe adeno-associated virus (AAV) as avector to carry therapeutic genes. We are developing gene therapy for intractable diseases of the central
nervous system area such as amyotrophic lateral sclerosis (ALS), Parkinson's disease, AADC deﬁciency.Our
gene therapy approaches are expected to have long-term eﬀects via single administration; therefore, we
believe that they will reduce medical expenses in our super-aged society and ensure their global
competitiveness against other approaches.

11

Life Innovation Center 414, 25-22, Tonomachi 3-chome, Kawasaki-ku,
Kawasaki-shi, Kanagawa 210-0821, JAPAN+81-44-589-5900
information-gtri@genetherapy-ri.com
http://www-en.genetherapy-ri.com/

Japan Radioisotope Association
Kawasaki TechnicalDevelopment Center

Radioisotope

R a d i a ti o n

D o s imetry

Manufacturing and distribution of radioisotope products,
R&D of radiation technology

Japan Radioisotope Association (JRIA) was established in 1951 and was reorganized as a Public Interest
Incorporated Association. Our mission has been to spread professional knowledge and technology on
radioisotope utilization, and ensure the stable supply, safety and security of radioisotopes by means of ourlifecycle management system from supply to disposal in compliance with the relevant regulations andISO9001.
HQ of JRIA in Tokyo is organizing and supporting our members and users from research, industry and medicalﬁelds to promote the safe use of radioisotopes, providing training courses, publications and professional
meetings etc.
<Activities of Kawasaki Technology Development Center>- R&D for the radioisotope products and radiation technology- Research and calibration service of the radiation dosimetry and radioactivity measurement. (ISO17025)- Manufacturing, import, quality testing, transport and distribution of the wide range of radioisotope products.
3-25-20, Tonomachi, Kawasaki-ku,
Kawasaki, Kanagawa 210-0821JAPAN+81-44-589-4357
09

info-sengen@jrias.or.jp
https://www.jrias.or.jp/e/index.html

State-of-art medical devicesices

Johnson & Johnson Institute,Tokyo Science Center

training centersafety use

Training center for medical devices
The centerʼ s curriculum includes surgical simulation using organ models, skills labs for endoscopic andorthopedic surgery, training for vascular disease and infection prevention. With state-of-art technology, thecenter promotes safe and optimal use of leading-edge medical equipment.
The institute provides not only world class education andtraining but environment for lifelong study for healthcare
professionals with diﬀerent background, now with eﬀective
investment and operation of digital contents.

13

3-25-19 Tonomachi, Kawasaki-ku, Kawasaki,
Kanagawa 210-0821+81-44-288-7050

mtamura8@its.jnj.com（Minako Tamura）

https://www.jnj.co.jp/about-jnj/
healthcare-professionals/education-facilities

JSR Corporationc h e m i s tr yb a c t e r i a l ﬂora

i n f o r m a ti c so m i c s a n a l ys is

Fusion area among novel medicine and informatics
Our company started out in the petrochemical industry and have expanded our business into display andsemiconductor business. Recently our focus set on the life science business, conducting joint research with
Keio University, and launching the JSR / Keio University Medical Chemistry Innovation Center (JKiC). The

14

research center focuses on the culture and omics analysis of bacterial ﬂora, which play a wide variety offunction in vivo, and aims at social implementation of seed
research taken from JKiC and external sources. In

3-103-9 Tonomachi, Kawasaki-ku, Kawasaki-shi

addition, we are working to support more eﬃcient and+81-3-6218-3517

eﬀective development by analyzing the accumulated

jsr̲koho@jsr.co.jp

technologies and omics analysis data using informatics.

Kanagawa Institute ofindustrial Science andTechnology (KISTEC)
Tonomachi Branchhttps://www.jsr.co.jp/jsr̲e/evaluating functionaly
of food
antiviral

analysisof transcriptomes

antimicrobial

photocatalyst

antibacterial

intestinal ﬂora

Evaluation and R&D of functional food and antibacterial/antiviral action.
As the reliable public research and development institute of Kanagawa, contributing to the realization of anenriched life and the regional economic development, bymeans of supporting innovation of SME and promoting
science and technology.

LiSE 4F, 3-25-13, Tonomachi, Kawasaki-ku,
Kawasaki, Kanagawa 210-0821 Japan+81-44-280-1177+81-44-819-2031
sks@newkast.or.jp（Regional Innovation Promotion Group,
Rsearch Support Section,

Research and Development Department）

10

Kawasaki City Institutefor Public Healthto protect the health of citizens

The Institute protects public health by enhancing the functionsof traditional health institutes and strengthening healthcrisis-management functions such as measures against infectious diseases,
for food safety and security,and environmental health measures.

16

Setting "to protect the health of citizens" as a keyword,
conducting in wide range of experiment, research andinvestigation regarding public health. By collaborating withother

research institutions, developing world-classresearch divisions based on public health.

Life Science & Environment Research Center,2nd ﬂoor,3-25-13

tonomachi,kawasaki-ku kawasaki+81-44-276-8250

40eiken@city.kawasaki.jp

Kawasaki Environment ResearchInstitute (KERI)

Environment

Research

Environmental
Technology
Information

A research base to solve environmental issues becoming diverse and complex
KERI promotes comprehensive research to solve environmental issues through monitoring and analysis of
atmospheric environment and river water quality, and collecting information about impacts of climate change.
KERI cooperates with companies that possessing excellent
environmental technologies in this city.
KERI also gathers and disseminates information on
outstanding environmental technologies and know-how

17Life Science & Environment Research Center (LiSE) 3F

3-25-13 Tonomachi, Kawasaki-ku, Kawasaki City,
Kanagawa Prefecture, Japan 210-0821

for environmental protection in the city, and hosts+81-44-276-9001

environmental seminars and environmental learnings for

30sojig@city.kawasaki.jp

residents in order to promote regional revitalization andinternational contributions in the environmental ﬁeld.

KAWASAKI INSTITUTE
OF INDUSTRIAL PROMOTION
Innovation Center of NanoMedicine(iCONM)http://eri-kawasaki.jp/english/

In-body hospitals TM

Smart nanomachine TM

Realization of in-body hospitals® by creating smart nanomachine®
Human resources from various countries, organizations and/or ﬁelds are confronting the ambition of“establishing in-body hospitals®” by combining wisdom from various perspectives. Supported by advanced
research level with 7% of Top1% citation index, science and technology that can autonomously detect
physiological abnormalities and perform diagnosis/treatment are getting closer to reality every day. In the ﬁeldof life science, which is expected to be the core of
Kawasakiʼ s industry in the next era, iCONM is the place of

3-25-14 Tono-machi, Kawasaki-ku, Kawasaki,
Kanagawa 210-0821 Japan

open innovation gathering industry, academia and+81-44-589-5700

government together under one roof. We are conducting
research to promote innovative health care through the11fusion of engineering and medicine.

iconmkanri@kawasaki-net.ne.jp
http://iconm.kawasaki-net.ne.jp

keio University Frontier Research＆Education Collaboration
Square at Tonomachi（Tonomachi Town-Campus）

Wellbeing

life sciencer e ge n e r a ti v e
medicineh e a l th c a r e

d a ta sc ienc esociali m p l e m e ntation

haptics

An Institution for research and education in the life sciences
The Tonomachi Town Campus was established in April 2016. Responsible as a core institution of the Japan
Science and Technology Agency (JST) Research Complex Promotion Program, it has linked up and cooperated
with research institutions, corporations, and local authorities concentrated in Tonomachi King Sky Front andthe surrounding area to create a Wellbeing Research Campus, where it has integrated and promoted “fusion
research,” “commercialization support,” “infrastructure development,” and “town planning,” in addition to its
educational activities aimed at implementing on-campus seeds at Keio University.
Now that a foundation has been built, these will be further developed to ensure that we are placed in theworld as a global research complex working to realize a well-being society, and to this end, we announced
the "Tonomachi well-being declaration̶toward the realization of a well-being city from Haneda-Tonomachi̶"in March 2020. Keio University will continue to play a central role in driving the growth of the Tonomachi
Research Complex. https://news-channel.jp/2020/03/13/482/

19

RGBT2-4A, 3-25-10, Tonomachi, Kawasaki-ku, Kawasaki City, Kanagawa 210-0821, Japan+81-44-201-7466
info@tonomachi-wb.jp（Yoshiyuki Kozuka）
https://www.tonomachi.keio.ac.jp/en/Life Science Institute,Inc.
Production Division,
Tonomachi CPC

Tonomachi CPC

Muse cell-based productR e g e n e r a ti v e M e d i c i n e

P r o d u c ti o n

R &D

R&D, Production of regenerative medicine
We established Tonomachi-CPC in October 2018 as a Cell Processing Center for Muse cell-based product.
Then, we obtained a license for marketing of regenerative medicine products in April 2018, and secured amanufacturing of regenerative medicine products at Tonomachi-CPC in July 2018.
Currently, clinical trials of Muse cell-based product are in progress for four indications (acutemyocardial
infarction, ischemic stroke, epidermolysis bullosa and spinal cord injury) and we plan to submit an application
for marketing approval for Muse cell-based product to PMDA(Pharmaceuticals and Medical Devices Agency ofJapan) in FY2020.
Here, Tonomachi-CPC is responsible for manufacturing Muse cell-based product for the above clinical
trials,preparing data relating to product and quality for the application for marketing approval.

25-22 Tonomachi 3chome,Kawasaki-ku,
Kawasaki-shi,Kanagawa 210-0821＋81-50-3188-2753
https://www.lsii.co.jp/en/inquiry/index.php
https://www.lsii.co.jp/en/index.html
12Material Research Center Co., Ltd

Contract Research

E x p e r i m e n ta l Animal

F u n c ti o n a l F o o dI evaluate the internal availability of the functional foods materialusing a experimental animal
In 1999, our company was established purpose with carry out an evaluative examination with scientiﬁc evidence
using by experimental animals. We determined the many kind of biomarkers focus on nutrition and toxicology ﬁelds.

21

These determinations based on methods as physiology, pathology, molecular biology and other science ﬁelds.

Many kinds of medicine or food products company or research organization asked to our company to evaluate
the function, bioavailability and others of original materials.
We consulted research plan and methods together andcarry out many evaluative examinations.
In addition, we developed and to sell the disposable
experimental animal care products.

Medtronic Japan Co.,Ltd.
Medtronic Innovation Center

LiSE-4F, 3-25-13, Tonomachi, Kawasaki-ku,
Kawasaki, Kanagawa 210-0821 Japan+81-44-287-2551

infoao@scitex-mrc.co.jp（Yoshiko

Medical Device

Aoyama）

I n n o v a ti on

T e c h n o l o g y S c o u ti n g

Contribute to Healthcare advancement& Therapy Innovation by providing educational programs
We strive to contribute to the healthcare advancement and restoration of patients' healthby providing the
cutting edge medical technologies in a wide variety of clinical ﬁelds.

223-25-10, Tonomachi, Kawasaki-ku, Kawasaki-shi,+81-44-280-5101

rs.japanmic@medtronic.com（Go Ikeda）

Metcela Inc.

R e g e n e r a ti v e m e d i c i n e

R&D of regenerative medicine products

13

Metcela is a pre-clinical stage biotech startup in Japan, developing an innovative, clinically viable and eﬀective cell therapy forheart failure. Metcela uses a speciﬁc population of ﬁbroblasts found in the heart, called “VCFs” or VCAM-1-positive cardiac
ﬁbroblasts. Since the ﬁrst discovery of VCFsʼ therapeutic eﬀects for heart failure, Metcela has been working closely with a group of
cardiologists, researchers and delivery device experts to develop clinically viable therapeutics and procedures.
Heart failure is a global pandemic that kills more people than any other ailments, yet there is no ultimate treatment for thisdebilitating condition. Most currently available treatment options only prevent the progression of the symptoms rather thanproviding a deﬁnitive cure for this irreversible condition. The lastresort for the heart failure patients is heart transplant, but the issue
Life Innovation Center #419, 3-25-22 Tonomachi,with a persistent shortage of the donor hearts remains.
Kawasaki-ku, Kawasaki-shi, Kanagawa 210-0821, Japan
Metcelaʼ s approach to heart failure therapy is quite unique from+81-44-201-8926
other technologies that attempt to simply replenish cardiomyocytes
in the infarcted areas. Instead, Metclea aims to stimulate pre-existing
admin@metcela.com（Kenichi Nogami）
endogenous cardiomyocytes to regenerate damaged cardiac tissue
https://www.metcela.com/
by re-establishing favorable microenvironments with VCFs.

Middle Molecule IT-based
Drug Discovery Laboratory（MIDL）,
Tokyo Institute of Technology

Drug discovery

Middle-molecule

Nucleic acid

PeptideMolecular simulation

Development of a middle molecule drug discovery platformthat utilizes computer science
The Middle Molecule IT-based Drug Discovery Laboratory (MIDL) was established in September of 2017 as one of the"Innovation Research Initiatives" at Tokyo Institute of Technology.

24

We are pioneering new middle molecule simulation

RGBT2-A, 1C

on-site applications for middle molecule drug discovery in close

Kawasaki, Kanagawa 210-0821,Japantechnologies and design methods and are proceeding with theircollaboration between researchers for computation andexperiments. In addition, by combining information technology
with advanced technologies for peptide and nucleic acidsynthesis the Institute owns, we aim to put them into practicaluse in middle molecule drug discovery.

MITSUBISHI LOGISTICSCROPORATION

3-25-10 Tonomachi, Kawasaki-ku,+81-44-589-8691

oﬃce@midl.titech.ac.jp（Dr. Fumio Kurayama）

http://www.midl.titech.ac.jp/en

Ultra Cold Chain

Logistics

Regenerative
Medicine

Investigational Products for
Human Cell therapy and Gene Therapy

Cell Banking

Logistics Services with Ultra Cold Chain
Mitsubishi Logistics has been operating a new typ of logistics facility at Life Innobation Center - a regenerative medicine
and cell therapy industrialization facility since August 2017. Equipped with liquid nitrogen tanks, medical freezers andother cryogenic banking equimpent, the logistics facility can handle dry shippers or containers to ship ultra frozen

25

products and is commisioned by major pharmaceutical companies and medical product wholesalers with the cellbanking, storage and transport of their products. Utilizing theknowhow aqquired to date through its medical logistics

Room 114, 3-25-22, Tonomachi, Kawasaki-ku,

regenerative medicine and cellular logistics.

+81 3 3278 6410

business, the company is strenghening its involvement in

Kawasaki, Kanagawa 210-0821 Japan

yoshi-sato@mitsubishi-logistics.co.jp（Yoshihiko Sato）
https://www.mitsubishi-logistics.co.jp/english/index.html

NanoCarrier Co., Ltd.

nanoparticles

nanomedicine

The R&D and manufacturing of new anticancer drugs withoriginated micellar nanoparticle technology
By encapsulation of drugs into micellar nanoparticles (20-100nm), NanoCarrier aims to develop especially anticancer

drugs that can deliver drugs more safely, eﬃciently and preferentially to cancer cells with longer circulation time in the
blood, thus resulting in reduced adverse reactions and increased therapeutic eﬃcacy. This technology has the strong
potential to achieve high therapeutic eﬃcacy with small dosage;
shorter treatment periods and reduced treatment costs; and144-15 Chuo, 226-39 Wakashiba, Kashiwa,

and improve their quality of life.

+81-4-7197-7621

alleviate the mental and physical burden placed on patients

Chiba, 277-0871, Japan

info@nanocarrier.co.jp
http://www.nanocarrier.co.jp/en/

14NANOEGG®
Research Laboratories, Inc.

drug delivery

e cz e m a

atopic dermatitis

n a n o - e n ca p s u l a t i o nl i q u i d cr y s t a ls k i n ca r e

d r u gss k i n s ci e n ce

co s m e ce u t i c al

A dermatological research lab, we venture outside the box
to pursue well-being and grace for all.

Nanoegg's R&D is focused on the skin.
Firstly, we developed technologies centered on drug delivery from the skin.
Our proprietary "nano-encapsulation technology" and "liquid crystal technology" allows for deeper penetration of active ingredients into thedermis, and we apply these technologies to materials and other
NANOEGG® Research Laboratories, Inc.
technologies. We hope one day this technology will lead to vaccine patches.
Innovation Center of NanoMedicine 4F,
Secondly, we elucidate skin diseases such as eczema and those that
Tonomachi 3-25-14, Kawasaki-ku, Kawasaki-shi,occur with aging. We hope to eventually establish a protocol on curing
Kanagawa 210-0821, Japan
atopic dermatitis.
Skin conditions hamper people's life in subtle ways. We challenge+81-44-400-1155
ourselves every day to research and develop solutions for diﬃcult
dermatological issues by focusing on the mechanism of symptoms andinfo@nanoegg.co.jp
change. Our goal is to raise people's quality of life throughhttps://www.nanoegg.co.jp/
dermatological research.

National Insutitute of
Health Sciences27

pharmaceuticalproducts

medical devices

regenertive
medical prodacts

foodliving environment
materials

regulatory science

A core research institute for regulatory science; science for medical supplies,
medical equipment, food, living environment materials, etc.
Issues pertaining to human health change with the times. Many new pharmaceuticals, foodstuﬀs, and substances used indaily living are being created. Given this, the NIHS serves to control the products that are generated by science andtechnology to make sure that they truly beneﬁt the generalpublic. In other words, NIHS works to ensure harmony between
scientiﬁc technology and human beings.

This kind of research is referred to as "regulatory science", and
it is an area in which we, the staﬀ of the NIHS, actively pursue
each and every day.

28

3-25-26, Tonomachi, Kawasaki-ku,

Kawasaki, Kanagawa 210-9501 Japan+81-44-270-6600
iken@nihs.go.jp

http://www.nihs.go.jp/english/

PeptiDream Inc.

macrocyclic/constrained non-standard peptides“Drug Discovery Powerhouse” with Peptide-Based Technology
A bio-venture company originated from the University of Tokyo. PeptiDream has more than a hundred of drug

discovery and development programs based on its unique proprietary Peptide Discovery Platform System（PDPS）,
including both its in-house and those in partnerships withJapanese and multi-national pharmaceutical companies.

3-25-23, Tonomachi, Kawasaki-ku, Kawasaki,
Kanagawa 210-0821 Japan+81-44-223-6612
t-iwata@peptidream.com（Toshiyuki Iwata）

https://www.peptidream.com/
15

Regenerative medicine

PharmaBio Corporation

Cell therapy

CancerContract Development and Manufacturing Organization
for cellular and tissue based products.
we stand at a new frontier of medical progress that holds unlimited potential to meet rising hopes and expectations.
Japanʼ s advanced healthcare, with its rigorous standards, has raised peopleʼ s trust in medicine. At the same time, theimmense costs and risks associated with new drug

development and approval highlight the need for accelerated
drug development solutions.

30

Life Inovation Center 2F, 3-25-22, Tonomachi,
Kawasaki-ku, Kawasaki city, Kanagawa,Japan 210-0821+81-44-874-6477

info@pharmabio.co.jp

http://www.pharmabio.co.jp/en/

Pharmacological Evaluation
Institute of Japan (PEIJ),
General Incorporated Association

Drugcardiotoxicity

MEA Parser

Public healthOrgan-on-a-chip

STEAM education

Non-proﬁt independent research institute to bridge between academia
and industry by education, research, and development.
PEIJ is a non-proﬁt pharmacology research institute. We are working with the activities globally for improvement in thereliability of the evaluation method of toxicity / safety and eﬃcacy used in the case of drug development and chemicalsafety as an "ADAPTER". We are also working for STEAM education for all in the SDGs.
■ MEA Parser for international researchers

PEIJ, member of the HESI Cardiac Safety Committee Myocyte Database Subteam, made and published "MEA Parser"

which converts the imported raw data of various MEA equipment (MED64, Maestro and MCS) into common binary dataon Windows, supported by AMED, so that it can be used internationally in research for in vitro drug eﬀects on human
iPSC derived cardiomyocytes. MEA Parser makes sense to store not only processed data but also raw data in the

database for veriﬁcation and open science. Every researcher using MED64/Maestro/MCS can access the converted

common binary data, and waveform an analysis can be carried out with their own ﬁlter and wave analysis tools.
Researchers can develop new endpoints in the international open science context.
■ Present a proposal for international standardization"Present a proposal for international standardization of a method for evaluating drug cardiotoxicity using iPS cell

technology" is a goal to be achieved by around 2020 in the Healthcare Policy. PEIJ published a paper on our "MEA
Parser" that shows the usefulness of the raw data of various MEA devices (Inutsuka T. The role of the “MEA Parser” :International release and perspectives. Curr Study Environ Med Sci 10.). PEIJ could suggest storage of the raw data inthe database in international standardization of the database.

Rm. 424, Life Innovation Center, 3-25-22

Tonomachi, Kawasaki-ku, Kawasaki, Kanagawa
210-0821 Japan+81-44-272-7187
peij@peij.or.jp
https://www.peij.or.jp/
16

Contractgene analysis

Riken Genesis Co.,Ltd.

clinicalsequencing

ISO15189

CLIA
laboratory

in vitro diagnostics

Genetic analysis services for clinical trials and research applications,development of in vitro diagnostics, etc.
Our mission is to realize personalized medicine using genomics and molecular diagnostic technologies, and we are
exploring businesses that use advanced genetic analysis technologies.

1. Clinical Sequencing Service: We are doing several actovities for clinical realization of "Cancer Clinical Sequencing" in Japan.

2. Drug development Support Service: From measurement of biomarkers in each phase of drug development todevelopment of in vitro diagnostics, to application for pharmaceutical aﬀairs, etc.
Our laboratories have obtained CLIA certiﬁcation and are able

32

Life Innovation Center 3-25-22 Tonomachi,

to conduct global clinical trials.

Kawasaki-ku, Kawasaki City, Kanagawa

3. Contract Gene Analysis Service: We provide a wide range of

210-0821 JAPAN

genetic analysis services, from whole exome analysis using+81 44 277 3611

NGS to verifying speciﬁc genes using digital PCR.

4. RUO and IVD: A wide range of research reagents are

info2@rikengenesis.jp

companion diagnostics for molecular target drug.

https://www.rikengenesis.jp/en.html

available for cancer and infectious diseases.We also provide

SBI Pharma Co., Ltd.

ALA

Porphyrin

Heme

Cancerhealth food(dietary supplements)

Cosmetics

Medicine

SBI Pharmaceuticals is conducting research and development for the purpose ofutilizing 5-ALA in the ﬁelds of cosmetics, health food, and medicine.

33

SBI Pharma Co., Ltd. Kawasaki Research institute has been established to provide innovative products in the ﬁelds ofcosmetics, health food (dietary supplements), and medicine by utilizing 5-ALA (5-Aminolevulinic Acid), which can be
mass-produced from the technology developed by COSMO OIL
Co., Ltd.The aim of SBI Pharma Co., Ltd. is to enrich our lives
through the development of innovative products using

5-ALA.The team at SBI Pharma Co., Ltd. will use its best eﬀorts
to meet the challenges in order to provide 5-ALA products toimprove the lives of our customers.

Sumitomo Dainippon PharmaCo., Ltd

Innovation Center of NaoMedicine(iCONM)4F, 3-25-14,

Tnomachi Kawasaki-Ku Kawasaki-Shi Knagawa,210-0821+81-44-382-0500

mishizuk@sbigroup.co.jp（Masahiro Ishizuka,Ph.D）
http://www.sbipharma.co.jp/english/index.html

Psychiatry and Neurology

Oncology

Regenerative medicine

Cell therapy

Manufacturing and sales of pharmaceuticals
Sumitomo Dainippon Pharma deﬁnes its corporate mission as "to broadly contribute to society through value creation

based on innovative research and development activities for the betterment of healthcare and fuller lives of people
worldwide". By pouring all our eﬀorts into the research anddevelopment of new drugs, we aim to realize our corporate

RGBT2-3C, 3-25-10, Tonomachi, Kawasaki-ku,
Kawasaki, Kanagawa 210-0821 Japansolutions to people not only in Japan but also around the+81-78-306-2170

innovative pharmaceutical products in the focus research areas

daiki-nukaya@ds-pharma.co.jp（Daiki Nukaya）

mission and provide innovative and eﬀective pharmaceuticalworld. Sumitomo Dainippon Pharma's goal is to createof Psychiatry & Neurology, Oncology and Regenerative
17

Medicine/Cell Therapy.

https://www.ds-pharma.com/

healthcare

diagnostics

h e m a t o l ogy

blood

life sciencep e r s o n a liz edm e d i c ine

Sysmex Corporation

Development, manufacture, sales and export/import of diagnostic instruments,
reagents and related software.

Sysmex Corporation is headquartered in Kobe, Japan and provides equipment, reagents and clinicalinformation systems necessary for in vitro diagnostic testing in more than 190 countries. Sysmex is a world
leader in the ﬁeld of hematology. As of January 2020, Sysmex has aﬃliated companies in about 40 countries
and has established a global system for R&D, production, sales and after-sales support.
SkyFront Research Campus (SFRC) is one of Sysmex's facility, which is located in Life Innovation Center. SFRC
was established to reinforce its R&D function of bioinformatics, such as genome analysis, which is one of theways to analyze personal testing or diagnosis information comprehensively, and is essential to realize
personalized medicine.
SFRC is working on technologies such as medical AI, bio-simulation, complex systems theory and otherleading-edge information technologies.

35

302, Life Innovation Center, 3-25-22, Tonomachi, Kawasaki-ku, Kawasaki, Kanagawa 210-0821 Japan+81-44-280-0400
www.sysmex.co.jp/en/contact/others̲corporate̲information̲csr/index.php
www.sysmex.co.jp/en/

Takara Bio Inc.

Bio t e c h n o l o g y

Genetic
engineering

R e g e n e r a t i v e m e d i c i n e p riduc ts

CDMO

Gene therapy

Unmet
medical needs

C anc er

THE BIOTECHNOLOGY COCPANYTM
Based on the corporate philosophy of “Contributing to the health of humankind through the development ofrevolutionary biotechnologies such as gene therapy” , Takara Bio leverages biotechnology, its fundamental
technology, to engage in Bioindustry Business and Gene Therapy Business. Since the launch of Japanʼ s ﬁrst
restriction enzymes (reagents for genetic engineering research), our Bioindustry Business provides high-quality
products and services to universities and companies around the world in the ﬁelds of research support and
CDMO (Contract Development and Manufacturing Organization) which handles development and production
support for regenerative medicine products. In Gene Therapy Business, we are advancing the development ofleading edge technologies, such as gene and cell therapies, to address unmet medical needs.

Nojihigashi 7-4-38, Kusatsu, Shiga 525-0058, Japan+81-77-565-6920
bio-ir@takara-bio.co.jp
http://www.takara-bio.com/
18

Inquiries
C o a s t a l A r e a I n t e r n a ti o n a l S tr a t e g y H e a d q u a r te r s
Te l . + 8 1 - 4 4 - 2 0 0 - 0 7 6 359kokuse@city.kawasaki.jp